natgillin/translations-raw huggingface dataset:
wherein the at least 12 contiguous unrearranged functional hVλ gene segments and the plurality of contiguous unrearranged functional hJλ gene segments are operably linked to the mouse k light chain constant region gene such that the unrearranged light chain variable region is capable of rearranging to form a rearranged human λ light chain variable region and the mouse expresses antibodies comprising a light chain comprising a variable domain encoded by the rearranged human λ light chain variable region and a constant domain encoded by the mouse k light chain constant region gene. 
Genetski modificirani miš prema zahtjevu 1, naznačen time, što miš u svom genomu dodatno sadrži endogeni lokus imunoglobulina lakog lanca K koji se sastoji od zamjene endogenih VK 1 JK genskih segmenta neraspoređenim humanim VA i JA genskim segmentima, te naznačen time, što su humani VA 1 JA genski segmenti operativno povezani s endogenim mišjim CK genom tako da miš izražava imunoglobulinski laki lanac koji sadrži humanu varijabilnu regiju A spojenu s mišjom konstantnom regijom K.
After 18 hours, the reaction is evaporated and the residue dissolved in water. 
Nakon 18 sati, rcakcijsku smjesu se ispari i ostatak se otopi u vodi.
A CAR according to claim 1 wherein the spacer lacks the intracellular domain of LNGFR. 
CAR prema patentnom zahtjevu 1 naznačen time što razmaknici nedostaje unutarstanična domena LNGFER.
An isolated antibody or fragment thereof, wherein the antibody or fragment thereof competes with mAb 0170 for binding to and blocking a triggering receptor expressed on myeloid cells-1 (TREM-1) having an amino acid sequence set for as SEQ ID NO:1 (human TREM-1), SEQ ID NO:12 or SEQ ID NO:21 (cynomolgus monkey TREM-1). 
Antitijelo ili njegov fragment u skladu sa patentnim zahtjevom 1 ili 2, koji se natječe sa mAb 0170 za vezivanje za SEQ ID NO: 12 ili SEQ ID NO: 21 koja predstavlja aminokiselinske sekvence TREM-1 cinomolgus majmuna, gdje mAb 0170 sadrži teški lanac koji sadrži sekvencu SEQ ID NO: 4, 1 laki lanac koji sadrži sekvencu SEQ ID NO: 5.
M (EDA)X, wherein M is a metal selected from the group consisting of zinc, iron, copper and manganese, EDA is ethylene diamine ligated to the metal, and X represents chloride or sulfate counterions selected to provide a neutral metal and/or ligand. 
M (EDA)X, pri čemu je M metal odabran iz skupine koju čine cink, željezo, bakar i mangan, EDA je etilen diamin je vezan na metal, i X predstavlja kloridne ili sulfatne protuione odabrane kako bi osigurali neutralni metal i/ili igand.
Compounds of formula (I): 
Spoj formule (I):
An in vitro method according to any of the preceding claims, wherein step a) comprises adding a metal chelating agent, such as EDTA, EGTA or citric acid. 
Postupak in vitro prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time, da korak a) obuhvaća dodavanje kelatnog sredstva za metal, kao što je EDTA, EGTA ili limunska kiselina.
is, in case of c being a single bond, either hydrogen or C1 to C6 alkyl, or in case of c being a double bond, CHR5, wherein R5 is the same as defined before; 
R: je, u slučaju ako je c jednostruka veza, bilo vodik ili C, do Cg alkil, ili u slučaju ako je c dvostruka veza, CHRe, gdje je Rs isti kao što je definirano ranije;
The method of claim 15 or claim 16, wherein the mouse MHC I locus is an H-2K locus, and the mouse MHC I polypeptide is an H-2K polypeptide. 
Metoda iz zahtjeva 15. ili zahtjeva 16. pri čemu je mišji MHC I lokus H-2K lokus, a mišji MHC I polipeptid H-2K polipeptid.
Smoking articles in accordance with the present invention are capable of providing the user with the sensations and benefits of cigarette smoking, without burning tobacco. 
Substituti prema sadašnjem izumu mogu da daju korisniku senzacije i blagodati pušenja cigareta, bez izgaranja duhana.
The support leg of claim 1, characterised in that it comprises exactly one rotating shaft alone, connected in a kinematic mechanism with the manoeuvring screw (5), the rotating shaft being the drive shaft (8). 
Nosivi krak prema zahtjevu 1, naznačen time, da on ima točno samo jednu rotacijsku osovinu koja je spojena na kinematički mehanizam s manevarskim vijkom (5), pri čemu ta rotacijska osovina je pogonska osovina (8).
Diafiltration against a SDS-free buffer is the preferred way of removing SDS e.g. 
Diafiltracija prema puferu bez SDS je preferirani način odstranjivanja SDS, na pr.
is selected from the group consisting of hydrogen, alkyl, arylalkyl, cycloalkyl, cycloalkylalkyl, heterocycle, heteroarylalkyl, and (NRCRD)sulfonyl; and 
R4 je odabran iz skupine koja se sastoji od vodika, alkila, arilalkila, cikloalkila, cikloalkilalkila, heterocikla, heteroarilalkila i (NRcRp)sulfonila; i
said first DNA molecule hybridizes specifically to the reverse complement sequence corresponding to SEQ ID NO:5 from about nucleotide position 1 through about position 11305, and wherein said second DNA molecule hybridizes specifically to SEQ ID NO:4 from about nucleotide position 21 through about nucleotide position 914. 
spomenuta prva DNA molekula specifično hibridizira obrnuti redoslijed komplementarne sekvence koja odgovara SEQ ID NO: 5 pozicije nukleotida od oko 1 do pozicije oko 11305, i pri čemu druga spomenuta DNA molekula specifično hibridizira SEQ ID NO: 4 nukleotidne pozicije od oko 21 do nukleotidne pozicije od oko 914.
Consequently, in a preferred embodiment, the total nitrogen content of the present composition, as determined by Nitrogen Determination (Kjeldahl Method), Method II (FNP 5), is less than 20%, more preferably less than 15%, most preferably less than 10% by weight of dry matter. 
Posljedično, u poželjnom ostvarenju, ukupni sadržaj dušika u sadašnjem pripravku, određen pomoću Određivanja dušika (postupak po Kjeldahlu), postupak II (FNP 5), je manje od 20%, poželjnije manje od 15%, najpoželjnije manje od 10% po masi suhe tvari.
A method of producing a powder layer or a granular layer comprising the steps of: 
PATENTNI ZAHTJEVI Postupak za proizvodnju praškastog sloja ili sloja granulata koji sadrži korake:
A compound having the following structure: or a pharmaceutically acceptable salt thereof, or a composition comprising the compound or pharmaceutically acceptable salt thereof and an excipient; for use in the treatment of a disease or disorder. 
HOMO Prah x x ili njegova farmaceutski prihvatljiva sol, pri čemu se on upotrebljava u liječenju bolesti ili poremećaja koja/i je odabran/a od sljedećih: genitalno-urinarni rak, glioblastom, rak tankog crijeva i rak dojke.
recovering a data symbol carried by a normal tone according to the detected position of the reserved tone, 
Postupak za prijem OFDM-a prema patentnom zahtjevu 3, naznačen time da se dalje sastoji od:
adding diethylene glycol monoethyl ether (DEGME) to rifaximin, in a molar ratio ranging from about 4:1 to about 500:1, at temperatures ranging from room temperature to 100° C. for a duration of time ranging from 5 minutes to 5 hours to provide a rifaximin solution; 
- > dodavanja dietilen-glikol-monoetil-etera rifaksiminu, u molarnom omjeru u rasponu od 10:1 do 100:1, na temperaturama u rasponu od sobne temperature do 100 "C u trajanju u rasponu od 5 minuta do 5 sati kako bi se dobilo otopinu rifaksimina; -
A composition as defined in any one of embodiments 1-8 or 12 or a granule as defined in embodiment 14 for use in medicine, such as for treatment of diabetes or obesity, wherein said composition is administered orally. EXAMPLES 
Pripravak u skladu s bilo kojim od patentnih zahtjeva 1-21 ili 29-36, naznačen time što je namijenjen upotrebi u medicini, primjerice u liječenju dijabetesa ili pretilosti, gdje se navedeni pripravak primjenjuje oralno.
An oil composition obtainable by a method of any one of claims 1 to 4. 
Sastav ulja dobiven postupkom sukladno bilo kojem od zahtjeva I do 4.
In an additional embodiment, a non-human animal of the invention further comprises at its endogenous non-human B2 microglobulin locus a nucleotide sequence encoding a human or humanized B2 microglobulin polypeptide, wherein the animal expresses the human or humanized B2 microglobulin polypeptide. 
Životinja prema zahtjevu 1, naznačena time, da nadalje na endogenom ne-humanom B2-mikroglobulin-lokusu, obuhvaća nukleotidnu sekvencu koja kodira humani ili humanizirani B2-mikroglobulin-polipeptid, pri čemu životinja izražava humani ili humanizirani B2-mikroglobulin-polipeptid.
The method according to claim 30, wherein the resinous adhesive coating composition provided to the drying cylinder includes a polyvinyl alcohol resin and a polyamidoamine resin. 
Metoda u skladu s patentnim zahtjevom 3, pri čemu sastav smolastog adhezivnog omotača koji se nalazi na cilindru za sušenje (80) sadrži smolu polivinilnog alkohola i smolu poliamidoamina.
A system for fixing profiles (2) according to claims 1 and 2, characterized in that the said settlement profile (1) has its outer side (13) and lower (14) walls grooved. 
Sustav za učvršćivanje profila (2) prema zahtjevu 1, naznačen time da navedeni ugradbeni profil (1) ima njegovu vanjsku stranu (13) i donje (14) stjenke izvedene ožljebljeno.
The resulting white residue was re-dissolved into 1:1 EtOH/water (30 mL) and diethyl acetylenedicarboxylate (2.4 mL, 15 mmol) was added. 
Dobiveni bijeli ostatak je ponovo otopljen u 1:1 EtOH/vodi (30 mL) i dodan je dietil acetilendikarboksilat (2.4 mL, 15 mmol).
A compound according to claim 1, wherein the compound is selected from: 
Spoj iz patentnog zahtjeva 8, gdje spoj je: zN N=N.
Thereby, the pieces of wood being used as starting material are such pieces that usually are termed as boards. 
Na taj način su komadi od drva, koji se koriste kao početni materijal, takvi komadi koji se obično nazivaju rubnici.
The benzothiophene oxide derivative or a salt thereof according to claim 1, wherein R1 is a hydrogen atom; and R2 is a hydrogen atom, a halogen atom or an alkoxy group. 
Derivat benzotiofen oksida ili njegova sol prema zahtjevu 1, naznačen time, da je R1 vodikov atom; i R2 je atom vodika, atom halogena ili alkoksi skupina.
In some embodiments described herein, the isolated antibody comprises the HCDR2 comprising the amino the amino acid sequence of SEQ ID NOs: 7, 135, 136, 137 or 138. 
-HCDR2 sadrži sekvence aminokiselina od SEK ID BR-a: 7, 135, 136, 137 ili 138; 1 c. -HCDRI sadrži sekvence aminokiselina SEK ID BR:6.
The pharmaceutical composition according to claim 19 wherein said composition is in the form of a tablet, capsule, powder, pellet, suspension, emulsion, cream, gel, ointment or paste. 
Farmaceutski pripravak prema patentnom zahtjevu 2 u obliku tablete, kapsule, praška, pilule, suspenzije, emulzije, kreme, gela, masti, losiona, disperzije ili paste.
10% to 45% by weight oat bran, wholegrain oat flour or a mixture thereof, and 
% do 45 masenih % zobenih mekinja, integralnog zobenog brašna ili njihove smjese, i
analysing internally stored historical ratios of pattern counts; or processing by a monitoring device and comparing with a predetermined threshold. 
analize unutarnje pohranjenih prethodnih omjera ili zbrojeva obrasca, ili obrade preko nadzornog uređaja i poredbe s prethodno određenim pragom.
providing and unrolling a coil (19) of polymer sheet (20) to form the thermoformed layer (7), 
(1) isporučivanje 1 odmotavanje namotaja (19) polimerskog lima (20) kako bi se formirao termoformirani sloj
Core: Core-A: In one embodiment, X is O or NR1; a is a single bond and b is a double bond. 
X je O ili NR! kad je veza a jednostuka veza; ili X je N kad je veza a dvostuka veza;
38) at its C-terminus, linked to a tat peptide for use in treating or effecting prophylaxis of stroke, epilepsy, hypoxia, traumatic injury to the CNS not associated with stroke, Alzheimer's or Parkinson's disease in combination with a mast cell degranulation inhibitor or anti-histamine, whereby the mast cell degranulation inhibitor or anti-histamine inhibits an inflammatory response due to mast cell degranulation inducible by the tat peptide. 
38) na njegovom C-završetku, vezanu na tat peptid za uporabu za liječenje ili za utjecanje na profilaksu moždanog udara, epilepsije, hipoksije, traumatske ozljede središnjeg živčanog sustava koja nije povezana sa kapi, Alzheimerove ili Parkinsonove bolesti u kombinaciji s inhibitorom degranulacije mastocita ili antihistaminikom, pri čemu inhibitor degranulacije mastocita ili antihistaminik inhibira upalni odgovor zbog degranulacije mastocita koji su inducibilni s tat peptidom.
Total cholesterol, HDL-cholesterol, and LDL-cholesterol are measured using the automatic analyzer Kodak Ektachem DT System (Eastman Kodak Company, Rochester, NY, USA). 
Ukupni holesterol te LDL-holesterol su mjereni uporabom automatskog analizatora Kodak Ektachem DT System (Eastman Kodak Company, Rochester, NY, USA).
The glass furnace of claim 15 wherein the well is part of the feed chamber and the conveyor is oriented generally vertically within the feed chamber. 
Peć za staklo opisana u skladu s patentnim zahtjevom 13, naznačena time,da je mehanizam dopreme smjese za pečenje jedan vijčani transporter koji je vertikalno orijentiran.
The method of claim 2, wherein the chemical entity is chosen from: 
Kemijski entitet u skladu s patentnim zahtjevom 1, gdje je kemijski entitet odabran od:
The tablet or capsule as defined in any one of claims 1-8 for use in treating a thromboembolic disorder. 
Tableta za upotrebu u liječenju tromboembolijskog poremećaja kao što je definirano u patentnom zahtjevu 6, gdje je tableta administrirana oralno dva puta dnevno.
wherein PG is an amino protecting group. 
VI gdje je PG zaštitna skupina za amino.
The reaction mixture was filtered, concentrated and resulting residue was taken up in water (200 mL). 
Reakcijska smjesa je filtrirana, koncentrirana i dobiveni ostatak je postavljen u vodu (200 mL).
An isolated nucleic acid molecule encoding the antibody of claim 1. A vector containing the nucleic acid molecule of claim 2. 
Izolirana molekula nukleinske kiseline, naznačena time, što kodira antitijelo ili njegov antigen-vežući fragment iz zahtjeva 1.
The composition of claim 1, the compound comprising a structure of Formula 7 or stereoisomer thereof or pharmaceutically acceptable salt thereof. 
Sastav iz patentnog zahtjeva 1, tvar sadrži strukturu Formule 7 ili njen stereoizomer ili njenu farmaceutski s prihvatljivu sol.
digital identification means (or based on digital data exchange). 
- - digitalnih identifikacijskih sredstava.
An antibody for use of any one of claims 1-13, a conjugate for use of claim 15 or a pharmaceutical composition of claim 16, for use in a method of treating or preventing a disease or disorder involving cells expressing CLD18A2. 
Protutijelo sukladno patentnom zahtjevu 1, konjugat sukladno patentnom zahtjevu 3 ili farmaceutski pripravak sukladno patentnom zahtjevu 4 za uporabu u postupku liječenja ili prevenciju bolesti ili poremećaja koji uključuje stanice koje eksprimiraju CLD18A2.
wherein in the above formulae R1 and R2 are independently, of each other, hydrogen or a nitrogen protecting group and R5 is hydrogen or alkyl. 
gdje su R1 i R2 u gornjim formulama, međusobno neovisno vodikova ili dušikova zašttina skupina i R5 je vodik ili alkil. 5
Known elastomer materials present problems when they are used as a material for the closure part or plunger disclosed respectively in WO-A-02/064439, WO-A-03/028785 or WO-A-04/08317. 
Poznati elastomerni materijali koji predstavljaju probleme kada se koriste kao materijal za element za zatvaranje ili za klip, otkriveni suu WO-A-02/064439, WO-A-03/028785 ili WO-A-04/08317.
A method for treating a patient suffering from an inflammatory or obstructive pulmonary disease or condition, the method comprising administering to the patient via an MDI a therapeutically effective amount of co-suspension as defined in any of statements 1 through 39. 
Ko-suspenzija u skladu s bilo kojim od patentnih zahtjeva 1 do 13, naznačena time što je namijenjena upotrebi u liječenje pacijenta koji boluje od upalne ili opstruktivne plućne bolesti ili stanja.
A kit of parts comprising (b) an antagonist of M3 muscarinic receptors as defined in claim 1 or 2 together with instructions for simultaneous, concurrent, separate or sequential use in combination with (a) a corticosteroid as defined in any one of claims 1 and 3 to 7 for the treatment of a human or animal patient suffering from or susceptible to a respiratory disease as defined in claim 11 or 12. 
Komplet dijelova koji sadrži (b) antagonist M3 muskarinskih receptora kako je definirano u patentnom zahtjevu 1 ili 2 zajedno s uputama za istovremenu, paralelnu, odvojenu ili sekvencijalnu uporabu u kombinaciji s B2 agonistom kako je definirano u zahtjevu 1 ili 3, naznačen time, da je namijenjen za uporabu pri liječenju pacijenata koji pate od ili su podložni bolestima dišnih putova kako je definirano u zahtjevu 7 ili 8.
The coating material as recited in claim 1, wherein the acid catalyst is selected from the group consisting of a strong Brønsted acid. 
Obložni materijal prema jednom od prethodnih zahtjeva, naznačen time, da su kiselinski katalizatori odabrani iz skupine koju čine Broensted-kiseline, poželjno organske sulfonske kiseline.
an amino acid sequence of light chain CDR1 selected from the group consisting of the amino acid sequence of SEQ ID NO:16 and an amino acid sequence having deletion, substitution, insertion, addition or a combination of two or more of these mutations for one to several amino acid residues in the amino acid sequence of SEQ ID NO:16; 
(ii) aminokiselinske sekvence od CDR1, CDR2 i CDR3 varijabilnog područja slabog lanca pojedinačno uključuju odnosnim redom: a) aminokiselinsku sekvencu od SEQ ID NO: 16; b) aminokiselinsku sekvencu od SEQ ID NO:17; 1 c) aminokiselinsku sekvencu od SEQ ID NO: 18.
An isolated host cell comprising a nucleic acid molecule of claim 20 . 
Stanica domaćin naznačena time što sadrži molekulu nukleinske kiseline prema zahtjevu 6.
After rapidly covering and stirring for 1 min at room temperature (ca. 
Brzo se pokrije 1 miješa se 1 min pri sobnoj temperaturi (pribl.
This element of the article provides the passageway which channels the vaporized aerosol forming substance into the mouth of the user. 
Ovaj element proizvoda osigurava prolaz koji kanalizira isparenu tvar za formiranje aerosola u usta korisnika.
a lateral opening provided in the tubular body, between the upstream end and the downstream end, to define a lateral conduit in the device in fluid communication with the axial conduit; 
– bočni otvor (3), koji se nalazi u navedenom cjevastom tijelu (2) između navedenog uzvodnog kraja (2a) i navedenog nizvodnog kraja (2b), koji omeđuje bočni vod u navedenom uređaju, u fluidnoj komunikaciji s navedenim aksijalnom vodom;
The process according to claim 4, wherein the mechanical treatment in step d) comprises subjection to a volumetric power input of 1-500 kW/m3 for a duration of 1-30 min. 
Postupak u skladu s patentnim zahtjevom 4, naznačen time, da mehanička obrada u koraku d) sadrži podvrgavanje volumetrijskom dovodu snage od 1-500 kW/m3 u trajanju od 1-30 minuta.
In applying increased temperatures, in particular applying temperatures > 90 °C, usually drying periods up to several minutes are sufficient for a satisfactory drying of the obtained veneer. 
Kod primjene povišenih temperatura, naročito kod primjene temperatura > 90"C, obično su razdoblja za sušenje do nekoliko minuta dovoljna za zadovoljavajuće sušenje dobivenog furnira.
A safety glove according to claim 8 or 9, wherein said attachment is made of polymeric materials such as polyamide. 
Zaštitna rukavica (2) u skladu s patentnim zahtjevom 6 ili 7, naznačena time što je navedeni dodatak (1) načinjen od polimernih materijala, poput poliamida.
The combination of any one of claims 1-3 wherein V is and R2 is hydrogen. 
Spoj prema patentnom zahtjevu 5, naznačen time što je V jednako [image] i R2 je vodik.
The method of any one of claims 1-3, wherein the method prevents particle aggregation and/or particle size increase upon lyophilization and resuspension or freezing and thawing of an aqueous composition comprising the particles. 
Postupak prema zahtjevu 1, pri čemu postupak sprječava agregaciju čestica i/ili povećanje veličine čestice prilikom liofilizacije i resuspenzije ili smrzavanja i topljenja vodenog sastava koji sadrži krute čestice.
It is understood that “treatment” in this context refers to an action that leads to an amelioration of the cancer condition(s). 
Razumije se da se,liječenje" u ovom kontekstu odnosi na djelovanje koje vodi poboljšanju stanja raka.
The invention provides a compound of Formula (I) 
HR P20140025 T1 PATENTNI ZAHTJEVI Spoj Formule (I)
detecting said DNA amplicon molecule, wherein detection of an amplicon comprising at least one of SEQ ID NO:1, SEQ ID NO:2 and the complement thereof is indicative of the presence of said DNA molecule in said biological sample. 
(d) detektiranje navedenog amplikona DNA molekule, pri čemu otkrivanje amplikona koji sadrži najmanje jednu od SEQ ID NO: 1, SEQ ID NO: 2 i njenih komplemenata ukazuje na prisutnost navedene DNA molekule u spomenutom biološkom uzorku.
is phenyl or pyridyl, which is para-substituted by Hal and/or meta-substituted by Hal or LA, in Subformula 18 
je fenil ili piridil, koji je para-supstituiran s Hal i/ili meta-supstituiran s Hal ili LA, u Podformuli 18
is selected from the group consisting of 
R' je izabran iz grupe koja se sastoji od
The carbamate analog of 42-0-(D-Fructosylcarbonyl)rapamycin is formed from an amino sugar wherein the carbohydrate moiety is attached to the carbonyl linker through the amino nitrogen atom of the amino sugar, thereby forming a carbamate linkage. 
Karbamatni analog 42-O0-(D-fruktozilkarbonil)rapamicin dobiven je iz amino-šećera gdje je ugljikohidratna jedinica pričvršćena na karbonilni veznik kroz amino-dušikov atom amino-šećera, čime nastaje karbamatna veza.
wherein the counter circuit is operable to count the number of clock pulses generated in the voltage controlled oscillator, using a signal input from the transmission wave as a reference signal, and the comparator is operable to compare the counted value with a reference value, and 
gdje je krug za brojanje (551) podešen za brojanje broja satnih impulsa odaslanih iz naponom upravljanog oscilatora (556), uz pomoć sinkronizacijskog impulsa, kojeg generira dio za prijem (101) u obliku impulsa referentnog signala;
positioning a tool on at least one side of a path of travel through a vehicle monitoring station; 
smještavanja alata (80;160) na najmanje jednoj strani putanje (20) kroz postaju za praćenje vozilo (110,120);
A method for treatment of newborn hypoxic-ischemic encephalopathy (NHIE) comprising administering to a newborn human suffering from NHIE a combination of cannabidiol (CBD) with therapeutic hypothermia, wherein the CBD is a non-CB1 agonist. 
Kombinacija fitokanabinoidnog kanabidiola (CBD) s terapijskom hipotermijom za upotrebu u liječenju hipoksične ishemijske encefalopatije kod novorođenčadi (NHIE).
A glycosylated human Serum Amyloid P (SAP) polypeptide for use in inhibiting the differentiation of monocytes into fibrocytes, wherein the SAP polypeptide comprises an N-linked oligosaccharide chain, and wherein at least one branch of the oligosaccharide chain terminates with a a2,3-linked sialic acid moiety. 
Glikozilirani humani serumski amiloidni P (SAP) polipeptid za upotrebu u inhibiranju diferencijacije monocita u fibrocite, naznačen time, da SAP polipeptid sadržava N-vezani oligosaharidni lanac 1 pri čemu barem jedna grana oligosaharidnog lanca završava s 02,3- vezanim ostatkom sijalične kiseline.